AJP - Renal Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Renal Physiol (January 2, 2007). doi:10.1152/ajprenal.00163.2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/4/F1132    most recent
00163.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Westerweel, P. E.
Right arrow Articles by Verhaar, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Westerweel, P. E.
Right arrow Articles by Verhaar, M.
Submitted on May 12, 2006
Accepted on December 27, 2006

End-Stage Renal Disease causes an Imbalance between Endothelial and Smooth Muscle Progenitor Cells

Peter Edwin Westerweel1, Imo E Hoefer2, Peter J Blankestijn3, Petra de Bree1, Dafna J Groeneveld1, Olivia van Oostrom1, Branko Braam3, Hein A Koomans3, and Marianne Verhaar4*

1 Vascular Medicine, University Medical Center Utrecht, Utrecht, Netherlands
2 Experimental Cardiology, University Medical Center Utrecht, Utrecht, Netherlands
3 Nephrology & Hypertension, University Medical Center Utrecht, Utrecht, Netherlands
4 Utrecht, United States; Vascular Medicine, University Medical Center Utrecht, Utrecht, Netherlands; Utrecht

* To whom correspondence should be addressed. E-mail: m.c.verhaar{at}umcutrecht.nl.

Patients with end-stage renal disease (ESRD) on hemodialysis have an increased risk of cardiovascular disease (CVD). Circulating endothelial progenitor cells (EPC) contribute to vascular regeneration and repair, thereby protecting against CVD. However, circulating smooth muscle progenitor cells (SPC) may contribute to adverse vascular remodeling. We hypothesized that an imbalance occurs between EPC and SPC in ESRD patients and sampled progenitor cells from forty-five ESRD patients receiving regular treatment. Our study is the first to show reduced numbers of CD34+KDR+ hematopoietic stem cell (HSC)-derived EPC (Type I EPC). Furthermore, monocyte-derived EPC cultured from mononuclear cells (Type II EPC) were reduced in number and had a reduced capacity to stimulate endothelial cell angiogenesis. In contrast, SPC outgrowth was unaffected. In vitro incubation with uremic serum impaired Type II EPC outgrowth from healthy donor mononuclear cells and did not influence SPC outgrowth. The hemodialysis procedure itself induced HSC apoptosis and caused an acute depletion of circulating EPC. Taken together, the decreased number and impaired function of EPC are compatible with impaired endogenous vascular repair in hemodialysis patients, while the unaffected SPC numbers suggest that the potential of progenitor cells to contribute to adverse remodeling is retained. This EPC-SPC imbalance may contribute to the acceleration of CVD in ESRD patients and could offer novel therapeutic targets.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
G. Krenning, P. Y. W. Dankers, J. W. Drouven, F. Waanders, C. F. M. Franssen, M. J. A. van Luyn, M. C. Harmsen, and E. R. Popa
Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease
Am J Physiol Renal Physiol, June 1, 2009; 296(6): F1314 - F1322.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
D. Hughes, A. A. Fu, A. Puggioni, J. F. Glockner, B. Anwer, A. M. McGuire, D. Mukhopadhyay, and S. Misra
Adventitial transplantation of blood outgrowth endothelial cells in porcine haemodialysis grafts alleviates hypoxia and decreases neointimal proliferation through a matrix metalloproteinase-9-mediated pathway--a pilot study
Nephrol. Dial. Transplant., January 1, 2009; 24(1): 85 - 96.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P. E. Westerweel, F. L.J. Visseren, G. R. Hajer, J. K. Olijhoek, I. E. Hoefer, P. de Bree, S. Rafii, P. A. Doevendans, and M. C. Verhaar
Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy
Eur. Heart J., November 2, 2008; 29(22): 2808 - 2817.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
P. Stenvinkel, J. J. Carrero, J. Axelsson, B. Lindholm, O. Heimburger, and Z. Massy
Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle?
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 505 - 521.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Y. Diao, S. Guthrie, S.-L. Xia, X. Ouyang, L. Zhang, J. Xue, P. Lee, M. Grant, E. Scott, and M. S. Segal
Long-Term Engraftment of Bone Marrow-Derived Cells in the Intimal Hyperplasia Lesion of Autologous Vein Grafts
Am. J. Pathol., March 1, 2008; 172(3): 839 - 848.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. Tongers and D. W. Losordo
Frontiers in Nephrology: The Evolving Therapeutic Applications of Endothelial Progenitor Cells
J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2843 - 2852.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
O. van Oostrom, M. Nieuwdorp, P.E. Westerweel, I.E. Hoefer, R. Basser, E.S.G. Stroes, and M.C. Verhaar
Reconstituted HDL Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes
Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1864 - 1865.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.